A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223Radium-dichloride.

about

A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223Radium-dichloride.

Item

http://www.wikidata.org/entity/Q47236071

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

A 3-variable prognostic score ...... ted with 223Radium-dichloride.

@en

A 3-variable prognostic score

@nl

type

Item

label

A 3-variable prognostic score ...... ted with 223Radium-dichloride.

@en

A 3-variable prognostic score

@nl

prefLabel

A 3-variable prognostic score ...... ted with 223Radium-dichloride.

@en

A 3-variable prognostic score

@nl

P1476

A 3-variable prognostic score ...... ated with 223Radium-dichloride

@en

P2093

Alessio Farcomeni

http://www.w3.org/2001/XMLSchema#string

Giulia Anna Follacchio

http://www.w3.org/2001/XMLSchema#string

Massimiliano Pacilio

http://www.w3.org/2001/XMLSchema#string

Roberto Pani

http://www.w3.org/2001/XMLSchema#string

Rosanna Pellegrini

http://www.w3.org/2001/XMLSchema#string

P2860

Recent progress in pharmaceutical therapies for castration-resistant prostate cancer

Radioisotopes for the palliation of metastatic bone cancer: a systematic review

Alpha emitter radium-223 and survival in metastatic prostate cancer

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.

Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.

Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC)--delayed response and flare phenomenon should be considered.

P2888

s12149-017-1228-6

P304

142-148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12149-017-1228-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe De Vincentis

Viviana Frantellizzi

P577

2017-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29285670

http://www.w3.org/2001/XMLSchema#string